With us on the podcast to talk about recent and upcoming biosimilar launches is Sean McGowan, senior director of biosimilars at AmerisourceBergen. McGowen spoke with us about what the US biosimilars market needs now in order to thrive and tells us which developments he’ll be watching closely in 2020.
For stakeholders in the US biosimilars market, the past few months have been exciting times. We’ve seen multiple product approvals, and the launch of a number of highly anticipated and long-awaited biosimilar products. With us on the podcast today to talk about these developments is Sean McGowan, senior director of biosimilars at AmerisourceBergen.
McGowan is responsible for leading strategy and business development initiatives for the biosimilar product category, and partners with biosimilar manufacturers in the precommercial, launch, and postlaunch phases. He also leads internal collaboration with customer groups to guarantee open access to biosimilars. McGowen spoke with us about the recent biosimilar launches in the United States, what the US biosimilars market needs now in order to thrive, and developments ahead in 2020.
Read more about the upcoming launches of multiple biosimilars from Pfizer, about Truxima, about Ziextenzo, and about Ogivri.